Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Unknown 5Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Rhabdomyosarcoma 4Rhabdomyosarcoma, Embryonal 2Rhabdomyosarcoma, Alveolar 2Sarcoma 1Hydatidiform Mole, Invasive 1Gestational Trophoblastic Disease 1Choriocarcinoma 1

Interventions

Radiotherapy 11pembrolizumab 10Nivolumab 10Doxorubicin 10Magnetic Resonance Spectroscopy 9Specimen Handling 8Cyclophosphamide 8Biopsy 7X-Rays 6Ipilimumab 6Radiation 5Phantoms, Imaging 5Ifosfamide 5talimogene laherparepvec 4cabozantinib 4Nuclear Medicine Department, Hospital 4Irinotecan 4tazemetostat 3selpercatinib 3pazopanib 3liposomal doxorubicin 3fludarabine 3Temozolomide 3Etoposide 3ulixertinib 2tislelizumab 2tipifarnib 2palbociclib 2larotrectinib 2ivosidenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Sarcoma × Dactinomycin × Clear all
NCT04388839 2025-11-26

Evolutionary Therapy for Rhabdomyosarcoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
12 enrolled
Sarcoma

Rhabdomyosarcoma, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡